Sugi Predict

Sugi Predict / Compounds / SCHEMBL23930488

SCHEMBL23930488

SCHEMBL23930488

CC(C(N)=O)N(c1ccc(F)cc1)c1nc(N)c(C(=O)c2cc(C(=O)NC(CF)CF)no2)s1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ POLB P06746 3/20 0.36
▸ CDK5 Q00535 4/20 0.34
▸ CDK5R1 Q15078 4/20 0.34
▸ NPC1 O15118 3/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ TP53 P04637 3/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ CCNA2 P20248 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ CNR2 P34972 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ CASP1 P29466 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30210925 1.00 MAPT (0.36) MAPTMEN1KMT2APOLBCDK5
SCHEMBL23930498 0.92 MAPT (0.38) MAPTMEN1KMT2APOLBCDK5
SCHEMBL30210848 0.92 MAPT (0.38) MAPTMEN1KMT2APOLBCDK5
SCHEMBL23930609 0.89 MAPT (0.37) MAPTMEN1KMT2APOLBCDK5
SCHEMBL28947148 0.89 MAPT (0.37) MAPTMEN1KMT2APOLBCDK5
SCHEMBL23930462 0.88 NPC1 (0.42) MAPTMEN1KMT2APOLBCDK5
SCHEMBL31411943 0.87 SMN1; SMN2 (0.38) MAPTMEN1KMT2APOLBCDK5
SCHEMBL25199172 0.87 SMN1; SMN2 (0.38) MAPTMEN1KMT2APOLBCDK5
SCHEMBL31633436 0.86 CCNA2 (0.37) MAPTMEN1KMT2APOLBCDK5
SCHEMBL23930595 0.86 CCNA2 (0.37) MAPTMEN1KMT2APOLBCDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4139287-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 — — EP claimed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 — — US claimed
EP-4139287-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2023-03-01 — — EP claimed
CN-115697979-A Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2023-02-03 — — CN claimed
WO-2021214020-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-10-28 — — WO claimed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 — — US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG MAPT 3251/4885MEN1 4290/4885KMT2A 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.